In a striking testament to South Korea’s growing biotech prowess, IM Biologics has captured the attention of investors and industry observers alike with its recent initial public offering (IPO) and a string of high-profile licensing deals. The company, founded in 2020 by a group of former HK Innoen researchers, has in just four years evolved from a research-driven spinout to a leading player in the field of dual antibody-based therapies for autoimmune diseases and cancer.
On March 11 and 12, 2026, IM Biologics opened its IPO subscription to the public, following a wave of institutional enthusiasm that saw the offering price set at the very top of the expected range—26,000 KRW per share. According to NewDaily, the institutional competition rate soared to 839.23 to 1, with about 76% of shares subject to lock-up commitments, underscoring robust confidence in the company’s prospects. The IPO is expected to raise 52 billion KRW, giving IM Biologics a projected market capitalization of around 384.2 billion KRW when it lists on the KOSDAQ on March 20, 2026.
The roots of IM Biologics’ success lie in its unique business model and scientific innovation. The company emerged as a fully independent ‘venture-type NewCo,’ a term used in the biotech industry to describe spinouts that operate without parent company equity ties. This independence, as highlighted by Green Economic News, has allowed IM Biologics to pursue bold research directions while forging strategic collaborations, most notably with US-based Navigator Medicines.
IM Biologics’ flagship therapy, IMB-101, is a dual antibody candidate targeting both OX40L and tumor necrosis factor (TNF) pathways. This approach is designed to treat hidradenitis suppurativa (HS), a chronic and painful autoimmune skin disorder with few approved therapies. The company’s unique angle is its dual-targeting mechanism and an extended dosing interval: while competitors like French pharma giant Sanofi are aiming for biweekly injections, IMB-101 aspires to be administered every 8 to 12 weeks—an advantage that could make it a ‘best in class’ therapy if proven effective.
“Unlike most unlisted biotech firms, we achieved operating profit for two consecutive years,” said CEO Kyung-Sik Ha at a recent press briefing, as reported by NewDaily. “We plan to accelerate research and development further, using both technology transfer revenue and IPO proceeds.” The company reported operating profits of 14 billion KRW in 2024 and is expected to post a profit again in 2025, a rare feat for a biotech firm at this stage.
The journey to profitability was catalyzed by a landmark technology licensing deal in 2024. IM Biologics signed a contract with Navigator Medicines, a US biotech firm specializing in global clinical trials, worth approximately 1.8 trillion KRW. The agreement included a non-refundable upfront payment of 40 billion KRW (or about 29 billion KRW, according to some reports), with the potential for additional milestone and royalty payments as development progresses. This deal not only validated IM Biologics’ technology but also provided the financial runway to expand its research pipeline.
Navigator Medicines now holds global rights (excluding Korea) to IMB-101 and its sister candidate IMB-102, and is driving clinical development forward. After completing Phase 1b trials in Australia, Navigator is preparing for Phase 2 trials in the United States. The company’s deep-pocketed backers include RA Capital Management, a top-10 US biotech venture capital firm with over 17 trillion KRW in assets and a track record of successful exits, including early investments in Moderna. Navigator’s CEO, Toshi Bert, previously served as COO at ChemoCentryx, which was acquired by Amgen for $3.7 billion.
This collaboration model, which brings together IM Biologics’ research strengths and Navigator’s clinical expertise, is designed to reduce risk and improve the odds of success—a point not lost on industry analysts. “It’s not just a fledgling company; by leveraging the NewCo model, they’ve reduced risks and increased their chances of success,” a biotech industry insider told Green Economic News. “IM Biologics’ technology is now in the hands of a team with global capital and top-tier talent, improving the likelihood of smooth progress.”
IM Biologics’ ambitions don’t stop at autoimmune diseases. The company’s proprietary platform, IM-Opdecon, enables the rapid design and optimization of antibody modalities tailored to specific targets and mechanisms of action. Using this technology, IM Biologics has expanded its pipeline to include IMB-201, an antibody-drug conjugate (ADC) that targets the HLA-G protein—a stealthy shield used by cancer cells to evade the immune system. IMB-201 is designed to break through this barrier and deliver anti-cancer agents directly into malignant cells, a cutting-edge approach that could one day transform cancer therapy.
The company’s funding structure further reflects its venture-driven approach. Major shareholders include CEO Kyung-Sik Ha, who will retain over 16% post-IPO, and institutional investors such as Atinum Growth Investment Association and KB Smart Scale-Up Fund. Notably, HK Innoen, the company’s originator, is not a direct shareholder but benefits from a revenue-sharing agreement on technology transfers, as explained by HK Innoen representatives to Green Economic News.
Looking ahead, IM Biologics plans to use the IPO proceeds to accelerate preclinical development of its core pipeline, expand into new therapeutic areas, and strengthen its R&D capabilities. The company aims to secure pivotal clinical data by 2027, which would pave the way for further technology licensing deals or strategic partnerships with global pharmaceutical giants. CEO Ha is optimistic: “With this IPO, we’ll speed up development of follow-up pipelines and achieve meaningful business results every year, ultimately growing into a global biotech capable of independent drug approvals.”
He added, “By 2028, we expect to achieve a quantum leap through a major deal with a global big pharma, and by 2032, we aim to launch IMB-101 globally, establishing ourselves as a leading biotech in the field of immune diseases.”
With 2 million shares on offer and about 23% of shares expected to be freely tradable post-listing, IM Biologics’ debut is being closely watched as a bellwether for the Korean biotech sector. While the company’s valuation will increasingly hinge on clinical progress and additional licensing successes, its rapid ascent and innovative partnership model mark it as a standout in a highly competitive field. Investors and patients alike will be watching to see if IM Biologics can deliver on its bold promises and reshape the landscape of autoimmune and cancer therapies in the years ahead.